Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Allergic Reactions02:06

Allergic Reactions

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allergy in the elderly: A case note review of referrals to an adult allergy clinic.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2018
Same author

Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules-the SPUtNIk study.

BMJ open respiratory research·2016
Same author

What proportion of adult allergy referrals to secondary care could be dealt with in primary care by a GP with special interest?

Clinical and translational allergy·2016
Same author

Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.

Allergy·2011
Same author

Diagnosis and management of hymenoptera venom allergy: British Society for Allergy and Clinical Immunology (BSACI) guidelines.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2011
Same author

Pollen-food syndrome is related to Bet v 1/PR-10 protein sensitisation, but not all patients have spring rhinitis.

Allergy·2011
Same journal

GWAS of Second-Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Basophil Activation Test Provides Additional Diagnostic Value Beyond Ara h 2-Specific IgE Testing in Peanut Allergic Adults.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Characterisation of Allergen Profiles in Commercial Egg Products to Inform Oral Immunotherapy Strategies in Egg Allergy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Allergic Diseases and Risk of Incident Autoimmune Diseases: Phenotype-Specific Patterns and Multimorbidity Effects in a Nationwide Cohort.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Determinants of Total and Inhaled Allergen-Specific Immunoglobulin E in the Middle-Aged and Elderly Population.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Rhinitis-Related Healthcare Utilization in Colombian Adults, 2015-2024.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Immunotherapy for allergic rhinitis.

S M Walker1, S R Durham, S J Till

  • 1Education for Health, The Athenaeum, Warwick, UK.

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|August 19, 2011
PubMed
Summary
This summary is machine-generated.

Allergic rhinitis (AR) management guidelines are updated for patients unresponsive to standard treatments. This guidance focuses on immunotherapy options, efficacy, and safety for improved patient outcomes.

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
06:08

Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay

Published on: September 22, 2023

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

Area of Science:

  • Allergy and Clinical Immunology
  • Pharmacology
  • Public Health

Background:

  • Allergic rhinitis (AR) impacts over 20% of the population in the UK and Western Europe, significantly affecting daily activities and sleep.
  • Standard treatments like intranasal corticosteroids and antihistamines are often insufficient for adequate symptom relief in many patients.
  • Existing management strategies necessitate updated evidence-based guidance for refractory cases.

Purpose of the Study:

  • To provide evidence-based guidance for the management of allergic rhinitis (AR) in patients not adequately controlled by standard therapies.
  • To outline indications, contraindications, patient selection, and efficacy of various immunotherapy approaches.
  • To address practical considerations, safety, cost-effectiveness, and future research directions for AR immunotherapy.

Main Methods:

  • Development of guidelines by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI).
  • Inclusion of BSACI member consultations via a web-based system for comprehensive feedback.
  • Evidence review and expert consensus for areas lacking data, focusing on immunotherapy efficacy and safety.

Main Results:

  • Comprehensive review of indications, contraindications, and patient selection for immunotherapy.
  • Evaluation of short- and long-term efficacy of subcutaneous and sublingual immunotherapy.
  • Discussion on safety profiles, different immunotherapy modes (pre-seasonal, co-seasonal), and practical aspects.

Conclusions:

  • The guideline provides a framework for utilizing immunotherapy in patients with AR who have failed conventional treatments.
  • It emphasizes evidence-based selection criteria, efficacy data, and safety considerations for immunotherapy.
  • The document also explores novel approaches, biomarkers, and future research avenues in AR management.